US approves updated Pfizer, Moderna shots targeting Omicron / Photo: Joseph Prezioso - AFP/File
-
Lancet study estimates Gaza death toll 40% higher than recorded
-
South Korea's presidential security chief resigns
-
Italian FM tours landmark mosque in first Syria visit
-
'Apocalyptic': ghastly remains of Malibu come into focus
-
Pakistan flight departs for Paris after EU ban lifted
-
Nicolas Maduro: Venezuela's iron-fisted 'worker president'
-
Ukraine's French-trained brigade rocked by scandal
-
Venezuela's Maduro to take presidential oath despite domestic, global outcry
-
Red-hot Gauff vows to keep cool in Australian Open title charge
-
Zverev says he has mindset to finally win Grand Slam in Melbourne
-
Anti-war Russian theatre in Latvia fights language ban
-
Nobel laureate Malala Yousafzai to visit native Pakistan for girls' summit
-
Shotgun watch: LA fire evacuees guard against looters
-
Los Angeles fire deaths at 10 as National Guard called in
-
'Control freak' Swiatek describes shock and 'chaos' over doping ban
-
Vietnam jails ex-lawyer over Facebook posts
-
Sinner in dark over verdict as ATP says doping case 'run by the book'
-
US President-elect Trump to be sentenced for hush money conviction
-
AI comes down from the cloud as chips get smarter
-
Englishman Hall grabs share of Sony Open lead
-
Olympic champ Zheng says 'getting closer' to top-ranked Sabalenka
-
Tajikistan bets on giant dam to solve electricity crisis
-
Air tankers fight Los Angeles fires from frantic skies
-
Right-wing disinformation targets DEI, 'liberal' policies as LA burns
-
Osaka to play Australian Open after 'devastating' injury pullout
-
'Disruptor' Medvedev ready to bring down Sinner and Alcaraz
-
Atletico can seize La Liga lead as Osasuna visit
-
Navalny lawyers face long sentences in 'extremism' trial
-
India's Kumbh Mela, world's largest religious gathering
-
India readies for mammoth Hindu festival of 400 million pilgrims
-
Uruguay bucks 2024 global warming trend
-
Last 2 years crossed 1.5C global warming limit: EU monitor
-
Asian markets drift lower as US jobs data looms
-
Sabalenka has 'target on her back' in pursuit of Australian Open 'history'
-
Croatia's populist president tipped for re-election
-
Veteran Monfils powers past teenager to reach 35th final
-
Japan 'poop master' gives back to nature
-
UN watchdog says Australia violated asylum seekers' rights
-
Murray braced for Djokovic ire in coaching debut at Australian Open
-
At CES, AI-powered garbage trucks reduce battery fire risk
-
S. Korea presidential security chief urges 'no bloodshed' in Yoon arrest
-
Combustible Kyrgios says tennis 'a bit mundane' without him
-
US Supreme Court to hear TikTok ban case
-
Los Angeles Rams playoff game moved to Arizona over fires: NFL
-
Survivors patrol as looters prey on fire-wrecked Los Angeles
-
US 'Pizzagate' conspiracy theory gunman killed by police: media
-
ATP chief insists Sinner doping case 'run by the book'
-
Musk promotes German far-right leader in latest European intervention
-
Inter Miami's Mascherano cools Neymar talk
-
Danish PM reaches out to Trump over Greenland remarks
NYSE - LSE
US approves updated Pfizer, Moderna shots targeting Omicron
US health officials on Wednesday authorized updated Covid-19 vaccinations by Moderna and Pfizer-BioNTech that specifically target the latest strains of the Omicron variant, with the goal of jump-starting a new booster campaign.
The two updated booster shots aimed at providing "better protection against Covid-19 caused by the Omicron variant" are approved for people age 12 and above for the Pfizer shot and 18 and older for Moderna, the Food and Drug Administration (FDA) said in a statement.
This new generation of anti-Covid vaccines targets both the original strain of coronavirus and the BA.4 and BA.5 lineages, the subvariants of Omicron that are causing the most cases in the United States and which the FDA predicts will circulate in the coming months.
Earlier this summer the US health department announced it had purchased 105 million doses from Pfizer and 66 million from Moderna for use over the fall and winter.
The vaccines have yet to be recommended by the Centers for Disease Control and Prevention, the nation's health protection agency. But an independent panel of experts is scheduled to be convened by the CDC on Thursday to discuss the updates.
CDC director Rochelle Walensky will be in charge of giving the final green light.
The new versions of the vaccines could potentially be available in the United States as early as next week.
"Receiving a booster that specifically targets the Omicron BA.4/.5 variant, currently the most prevalent strain of SARS-CoV-2, is an important public health measure that people can take to help protect themselves, especially as we head into a season filled with indoor gatherings," Moderna chief executive Stephane Bancel said in a statement.
The vaccines currently in circulation target the initial strain of the virus that first appeared in Wuhan, China. But they have gradually proven to be less effective against the variants that have appeared over time, due to rapid evolution of the virus.
In contrast to the Alpha and Delta variants, which eventually waned, Omicron and its subvariants have come to dominate infections worldwide in 2022.
Pfizer and Moderna have also filed for approval of their updated vaccines with the European Medicines Agency.
A.Magalhes--PC
